Filter Results
Filter Results
Allogeneic (38) Autologous (44) Bioconjugates/ADC (17) Exosomes (17) Expression Technologies (85) iPSCs (31) Mammalian (100) Microbial (19) mRNA (15) Parenteral Drug Product (32) Small Molecules (188) Viral Vectors (49)
Antibody Drug Conjugates (29) Bioavailability Enhancement (80) Bispecific Antibody (73) Difficult to Express Proteins (51) Drug device combinations (1) Drug Substance (API/HPAPI) (69) Enhanced ADCC (12) Fabs, Fusion, Scaffold and other Recombinant Proteins (29) Inhalation (35) Injectables (6) Lipid Nanoparticle Encapsulation (4) Monoclonal Antibody (73) Oral Drug Products (91) Particle Engineering (49) Solid Form Services (13)
Analytical Development (56) Antibody Humanization & Deimmunization (5) API Services (38) Bispecific DNA-to-IND (14) Cell Line Development (66) Clinical Supply Services (53) Commercial Supply Services (38) Early De-risking & Optimization (41) Fabs and Fc-Fusion proteins DNA-to-IND (2) First-in-Human Services (55) Formulation Development and Optimization (85) Ibex® Dedicate (3) Immunogenicity Assessment (11) IND-to-BLA (18) mAb DNA-to-IND: Ibex® Design (12) Manufacturing: cGMP (53) Manufacturing: GMP Drug Product (19) Manufacturing: GMP Drug Substance (38) Manufacturing: Non-GMP Manufacture (4) Parenteral Drug Product Development (12) PBPK Modeling (11) Process Development and Optimization (79) Regulatory Services (33) Scaffolds and Other Recombinant Proteins DNA-to-IND (2) Solid Form Services (5) Special Analytical Services (2) Strain Development (7) Tech Transfer (7) Tissue Acquisition (6) Viral Vector Expression Technologies (18)
4D-Nucleofector LV (4) bYlok™ Bispecific Antibodies Technology (16) Cocoon® Platform (26) GS Discovery® (11) GS Effex® (13) GS Gene Expression System® (50) GS piggyBac® Transposon System (45) GS Xceed® Gene Expression System (52) GSquad® Vectors (31) Hot Melt Extrusion (27) LNP (4) Mammalian Expression Technologies (66) Microbial Expression Technologies (19) Micro-dosing/Powder-in-capsule (14) Micronization (17) MODA® (5) Modified and Delayed Release (9) Particle Size Reduction (27) Spray Dried Dispersions (55) Taste-masking and Multiparticulates (12) Technology Selection (20) Viral Vector Expression Technologies (18) XS Technologies® (8)
Article (64) CDMO Notes Blog post (8) e-book (11) Interview (6) Peer-reviewed publication (35) Podcast (40) Poster (33) Presentation (on-demand) (31) Presentation (slides) (13) R&D Blog post (23) Report (1) Technical/Service brief (41) Video (19) Webinar (on-demand) (154) White paper (100)
   Loading...
Showing 1‐28 of 500
White paper
10 min read
Unlock Key Insights: Executive Summary of Our "End-to-End Regulatory CDMO Solutions" Webinar
Navigating the complex world of drug development and regulatory approval just got easier. Our recent webinar, "End-to-end regulatory CDMO solutions: development, manufacturing, and approval," offered invaluable insights into streamlining your journey from...
Webinar (on-demand)
25 min read
Lonza's integrated ADC offering: From concept to commercialization
As the Antibody-Drug Conjugate (ADC) market continues its robust expansion, the demand for specialized manufacturing expertise is paramount. Lonza, a leading CDMO, offers a complete end-to-end solution that simplifies the value chain and accelerates the t...
Webinar (on-demand)
55 min read
Solving the inhalation puzzle: A CDMO's guide to dry powder development
Unlock the secrets to successful pulmonary and nasal drug delivery with our exclusive on-demand webinar: "Solving the inhalation puzzle: A CDMO's guide to dry powder development." Inhalation and nasal delivery are transforming how we deliver therape...
Webinar (on-demand)
Navigating the CMC regulatory landscape during protein medicinal product development and manufacturing
Explore the evolving regulatory landscape for protein-based therapeutics in this on-demand webinar. Gain strategic insights into Chemistry, Manufacturing, and Controls (CMC) requirements across the product lifecycle—from preclinical development to market ...
CDMO Notes Blog post
10 min read
Fit-for-purpose analytical methods to accelerate the development and manufacture of new molecular formats
Learn how Lonza's experts develop fit-for-purpose analytical methods to ensure quality, consistency, and regulatory success for complex biologics. Read more.
CDMO Notes Blog post
10 min read
Smarter expression approaches for multi-chain therapeutic protein formats
Our customers play a critical role in driving innovation, often advancing multi-chain and new therapeutic formats to transform patient outcomes. To keep pace, cutting-edge therapeutic protein expression technology is essential - boosting titers, product q...
R&D Blog post
4 min read
Monitoring residual host cell proteins in pharmaceutical products to ensure patient safety
Biologics manufacturing mostly relies on host organisms, such as Chinese hamster ovary (CHO) cells and Escherichia coli, to produce therapeutic proteins.
White paper
10 min read
Precision in miniature: optimizing multiparticulate formulations for pediatric oncology
This white paper details a collaborative effort between Lonza’s Bend, OR site and Pfizer’s Groton, CT team to develop a robust commercial control strategy for a pediatric dosage form for crizotinib (Xalkori) in a material sparing fashion. The multiparticu...
Webinar (on-demand)
50 min read
Continuous flow techniques for pharmaceutical manufacturing at Lonza
Traditional batch reactors have served us well, but what if there was a more efficient, cost-effective, and robust way to produce pharmaceuticals and fine chemicals? In this on-demand webinar, we dive into the world of continuous flow processes...
White paper
10 min read
Better, faster small-molecule synthesis: leveraging modern tools to evaluate and optimize process chemistry
Lonza’s Advanced Synthesis family of solutions for testing and optimizing synthetic processes assist drug developers in navigating the path from discovery to commercialization. As small-molecule APIs become more complex, AI-enabled route scouting, HTE, ...
Technical/Service brief
5 min read
GS Effex® Cell Line for Enhanced Antibody Effector Function
GS Effex® derived from Lonza's leading GS Xceed® cell line, has been engineered to lack the enzyme responsible for the addition of fucose, α1,6-fucosyltransferase. This industrially relevant cell line produces antibodies free of fucose with enhanced...
Technical/Service brief
1 min read
XS Technologies® Microbial Platform for Protein Expression Brochure
XS Technologies® are the microbial expression systems for today’s therapeutics. While achieving yields of up to 20 g/L for simple proteins and up to 12 g/L for more complex proteins, they merge simplicity and scalability. XS Technologies® Expression Syste...
Article
5 min read
Navigating the Future of Bioconjugates and ADCs: An Expert Q&A with Iwan Bertholjotti
Webinar (on-demand)
60 min read
Unlock the future of drug development with PBBM and solid form screening for early-phase success
Struggling with poor bioavailability in your early-phase drug candidates? You're not alone. Low aqueous solubility is a common hurdle, delaying critical First-in-Human (FIH) trials and inflating costs. But what if you could accelerate development...
Article
10 min read
Empowering smarter decisions in drug development through modeling, AI and scientific expertise
Webinar (on-demand)
52 min read
Building Better Biologics: Early strategies for optimizing the progression of biotherapeutic candidates to first in human studies and beyond
The early stages of biologic drug development are critical to long-term clinical and commercial success. As biologics become more complex, an integrated approach to candidate selection, preclinical evaluation, and manufacturing readiness is essential. Th...
Poster
3 min read
Cocoon® platform demonstrates compatibility with off-the-shelf process analytical technologies
The Lonza Cocoon® Platform uniquely addresses the challenges of automated cell therapy manufacturing by enabling at-line integration of a variety of complementary systems such as Process Analytical Technologies (PAT) and electroporation. The integration o...
Poster
3 min read
End-to-end production of t cells on the Cocoon® platform, using buoyancy-activated cell sorting (bacs) for direct isolation from leukopaks
High-purity, viable T cell isolation is essential for consistent upstream processing of CAR-T cell manufacturing. Traditional magnetic cell separation uses positive or negative selection; the latter preserves cell integrity by avoiding activation and rece...
Technical/Service brief
10 min read
Elevate expression with the GSquad® Pro vector system
At Lonza, we continually invest in innovation covering all platform elements to help ensure that we keep one step ahead of the output from drug discovery groups. To ensure that the genetic instructions delivered into CHO cells at transfection can leverage...
Technical/Service brief
5 min read
Room to Grow: Exploring the Capabilities of 15,000L Microbial Manufacturing
Scaling microbial processes requires more than capacity - it demands precision, flexibility, and deep technical insight. This brochure introduces you to Lonza’s 15,000L microbial fermentation facility in Visp, Switzerland - one of the few of its kind glob...
White paper
10 min read
Industry-backed, data-driven approaches to enhancing container closure integrity
Container closure integrity (CCI) is central to ensuring product quality and patient safety. Our science- and risk-based approach integrates CCI across the full product lifecycle, from development to distribution. This white paper outlines how w...
Technical/Service brief
5 min read
Rapid Cocoon® CAR-T: rapid manufacturing of CAR-T cells with integrated selection in the Cocoon® platform
Integrated magnetic separation capabilities enrich for a pure T cell input To enable rapid manufacturing (RM) of CAR-T cells, an upstream T cell selection step is often preferred to ensure generation of a high-purity product. The Lonza Cocoon® Platform...
Podcast
2 min read
A View On Smart Capsule Technology (S04 E05)
In this episode, we’re joined by Karsten Lindhardt, Founder and CEO of Biograil, to explore how a spring-loaded oral capsule could revolutionize drug delivery—offering patients a needle-free alternative with the same therapeutic impact as subcutaneous inj...
Presentation (on-demand)
26 min read
Overcoming biotherapeutic protein expression challenges with advanced vector technology for a range of multi-gene and difficult to express proteins
The development of biotherapeutic products is complex and the growing prevalence of next-generation and difficult-to-express formats places increasing demands on CHO expression systems to deliver high yield, scalable, and quality-consistent bioproduction....
Webinar (on-demand)
Dry powder for intranasal delivery
This webinar is your chance to get ahead in the world of drug delivery. We're talking about intranasal dry powders—a game-changer that's set to transform how we administer medicine. If you're looking for the next big thing in pharmaceutical...
Webinar (on-demand)
Industrialization of AAV Manufacturing With Xcite® Transient and Stable Production Platforms
In this presentation, our experts Suparna Sanyal and Peng Wang take you deep into the industrialization of AAV (Adeno-Associated Virus) manufacturing. The session looks at two powerful production platforms: Xcite® Transient Transfection and Stable Produce...
Article
10 min read
Streamlining early phase drug development with continuous flow technologies
As small molecule complexity increases, early-stage development faces new challenges that demand innovative solutions. At Lonza Advanced Synthesis the continuous flow process is integrated into early phase development, allowing for optimization of chemica...
Poster
Adeno-associated virus characterization using nanopore long read sequencing and analysis
Recombinant adeno-associated virus (rAAV) has become a leading vector for in vivo gene delivery. The quality of the AAV product is crucial for the success of gene therapy, and thorough understanding of the viral genome sequence is becoming essential for e...